A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma-Reference-Cited by-同舟云学术

A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma

Published:2021-01-03 Issue:2 Volume:100 Page:437-443
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Oliva Stefania^ORCID,De Paoli Lorenzo,Ruggeri Marina,Caltagirone Simona,Troia Rossella,Oddolo Daniela,D’Agostino Mattia,Gilestro Milena,Mina Roberto,Saraci Elona,Margiotta Casaluci Gloria,Genuardi Elisa,Bringhen Sara,Boccadoro Mario,Omedé Paola

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-020-04384-w.pdf

Reference27 articles.

1. Bolli N, Avet-Loiseau H, Wedge DC, van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JMC, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammas MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC (2014) Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:2997. https://doi.org/10.1038/ncomms3997

2. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M, Getz G, Golub TR, Anderson KC, Richardson P, Krishnan A, Lonial S, Kaufman J, Siegel DS, Vesole DH, Roy V, Rivera CE, Rajkumar SV, Kumar S, Fonseca R, Ahmann GJ, Bergsagel PL, Stewart AK, Hofmeister CC, Efebera YA, Jagannath S, Chari A, Trudel S, Reece D, Wolf J, Martin T, Zimmerman T, Rosenbaum C, Jakubowiak AJ, Lebovic D, Vij R, Stockerl-Goldstein K (2014) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25:91–101. https://doi.org/10.1016/J.CCR.2013.12.015

3. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ (2015) Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 33:3911–3920. https://doi.org/10.1200/JCO.2014.59.1503

4. Fonseca R (2003) Many and multiple myeloma(s). Leukemia 17:1943–1944. https://doi.org/10.1038/sj.leu.2403090

5. Fonseca R, Barlogie B, Bataille R et al (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64:1546–1558. https://doi.org/10.1158/0008-5472.can-03-2876

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells;Blood Cancer Journal;2024-06-07

2. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial;The Lancet Oncology;2023-01

3. Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma;European Journal of Haematology;2022-12-04

4. Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal;Cancers;2022-10-26

5. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee;Blood Cancer Journal;2022-06-29